Effects of Low-Dose, Controlled-Release Phentermine/Topiramate (PHEN/TPM) on Weight, Glycemic Markers, and Progression to Type 2 Diabetes Mellitus (T2DM)

被引：0

|

作者：

Ryan, Donna H.

Gadde, Kishore

Wilson, Leland F.

Troupin, Barbara

机构：

来源：

DIABETES | 2010年 / 59卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：A491 / A491

页数：1

相关论文

共 50 条

[1] Low-Dose, Controlled-Release Phentermine/Topiramate (PHEN/TPM) and Markers of Type 2 Diabetes Mellitus (T2DM)
Ryan, Donna H.
Gadde, Kishore
Troupin, Barbara
Tam, Peter
DIABETES, 2010, 59 : A482 - A482
[2] Low-Dose Controlled-Release Phentermine/Topiramate (PHEN/TPM CR) For Weight Loss and Management of Type 2 Diabetes Mellitus (T2DM)
Garvey, W. Timothy
Peterson, Craig
Troupin, Barbara
OBESITY, 2010, 18 : S154 - S155
[3] CONTROLLED-RELEASE LOW-DOSE PHENTERMINE/TOPIRAMATE (PHEN/TPM CR) REDUCES WEIGHT, IMPROVES GLYCEMIC MARKERS, AND DECREASES PROGRESSION TO TYPE 2 DIABETES MELLITUS (T2DM) IN OVERWEIGHT AND OBESE PATIENTS WITH OBESITY-RELATED COMORBIDITIES.
Troupin, B.
Hankin, C. S.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S38 - S38
[4] A Low-Dose, Controlled-Release Formulation of Phentermine/Topiramate (PHEN/TPM) Demonstrates Significant Weight Loss, Clinical Improvement in Overweight/Obese Patients with Type 2 Diabetes Mellitus (T2DM) or Prediabetes
Gadde, Kishore
Najarian, Thomas
Day, Wesley W.
DIABETES, 2010, 59 : A101 - A101
[5] Long-Term Weight Loss and Improvement in Glycemic Parameters with Low-Dose, Controlled-Release Phentermine/Topiramate (PHEN/TPM CR)
Kushner, Robert F.
Garvey, W. Timothy
Troupin, Barbara
Day, Wesley W.
DIABETES, 2011, 60 : A515 - A515
[6] Long-term glycaemic effects of weight loss with low-dose, controlled-release phentermine/topiramate (PHEN/TPM CR) in overweight/obese subjects with diabetes
Van Gaal, L. F.
Cheskin, L. J.
Najarian, T.
Day, W. W.
Peterson, C. A.
DIABETOLOGIA, 2011, 54 : S371 - S371
[7] Low-dose, controlled-release phentermine/topiramate (PHEN/TPM) improves cardiovascular disease (CVD) risk factors
Tonstad, S.
Davidson, M.
Peterson, C.
Troupin, B.
EUROPEAN HEART JOURNAL, 2010, 31 : 806 - 806
[8] BUDGET IMPACT OF PHENTERMINE AND TOPIRAMATE EXTENDED-RELEASE (PHEN/TPM ER) IN OVERWEIGHT AND OBESE PATIENTS WITH COMORBID PREDIABETES OR TYPE 2 DIABETES MELLITUS (T2DM)
Zagadailov, E.
Carlton, R.
Bramley, T.
Liu, W.
Karnawat, S.
McDowell, J.
VALUE IN HEALTH, 2014, 17 (03) : A242 - A242
[9] Improvements in Dyslipidemia and Other Cardiometabolic Disease Risk Factors with Low-Dose, Controlled-Release Phentermine/Topiramate (PHEN/TPM)
Garvey, W. Timothy
Gadde, Kishore
Wilson, Leland F.
Peterson, Craig
DIABETES, 2010, 59 : A290 - A291
[10] Changes in Insulin Sensitivity in Overweight/Obese Patients Treated with Low-Dose, Controlled-Release Phentermine/Topiramate(PHEN/TPM)
Garvey, W. Timothy
Gadde, Kishore
Tam, Peter
Peterson, Craig
DIABETES, 2010, 59 : A481 - A481

← 1 2 3 4 5 →